Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease
Our findings highlight that post-CAR T-cell progression in MM is heterogeneous and that EMD confers an adverse prognosis, emphasizing the critical need for imaging surveillance. Strategies such as bridging therapies aimed at reducing tumor burden prior to CAR T-cell infusion or maintenance therapies post-CAR T-cell therapy warrant further investigation to optimize responses and improve long-term survival in this high-risk population.
Authors
- Omar Castaneda
- Frederick Lundry Locke (ORCID: https://orcid.org/0000-0001-9063-6691)
- Gabriel De Avila
- Kenneth H. Shain (ORCID: https://orcid.org/0000-0003-4178-8888)
- Fnu Amisha (ORCID: https://orcid.org/0000-0002-5110-3443)
- Hien D. Liu (ORCID: https://orcid.org/0000-0002-9945-4381)
- Taiga Nishihori (ORCID: https://orcid.org/0000-0002-2621-7924)
- Wenyi Fan (ORCID: https://orcid.org/0000-0002-7875-7404)
- Ziad Abuhelwa (ORCID: https://orcid.org/0000-0002-0031-7150)
- Rachid Baz (ORCID: https://orcid.org/0000-0003-4538-4733)
- Ariel Felipe Grajales-Cruz (ORCID: https://orcid.org/0000-0003-0999-1771)
- Brandon Jamaal Blue (ORCID: https://orcid.org/0000-0003-0639-3768)
- Melissa Alsina (ORCID: https://orcid.org/0000-0003-4946-823X)
- Ciara Louise Freeman (ORCID: https://orcid.org/0000-0001-5099-2843)
- Doris K. Hansen
Institutions
- University of South Florida (US)
- Moffitt Cancer Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-27
- DOI
- https://doi.org/10.3389/fonc.2025.1663814
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00